Bramacare launches new AI platform to improve eating disorder care
Lucy Batizovsky | March 31, 2026 | News story | Market & Product Development | AI, Bramacare, eating disorders
Bramacare has launched an AI-enabled platform designed to aid eating disorder and rehabilitation services, the first of its kind in the UK.
An intuitive system designed to reduce fragmentation between care services, AMY integrates physical health monitoring, risk stratification, multidisciplinary care planning and regulatory compliance to create a single shared patient record and care plan.
Developed by a clinical design team with direct specialist eating disorder experience, AMY was built around the Medical Emergencies in Eating Disorders (MEED) guidelines to support safer, faster and more consistent decision-making and make clinical governance structural rather than procedural.
The platform aims to achieve this by time-stamping and tracking alerts to resolution and automatically generating audit trails to create an evidence base for every patient interaction.
Using AI, continuous risk stratification can occur across multiple domains, including suicide and self-harm, falls, ligature risk and medication-related concerns, with risk profiles updating automatically as new information is entered.
Information can then be routed to senior clinicians, GPs, consultants, acute services or safeguarding leads through configurable escalation pathways.
By automatically monitoring schedules, flagging missing observations and overdue investigations and generating safeguarding and compliance reports, Amy will provide real-time dashboards showing service-level risk and performance to managers and safeguarding leads.
With at least 1.25 million people in the UK living with an eating disorder, the launch comes as demand and pressure on specialist services rises.
Increasing by almost 40% since the pandemic, the number of children and young people starting treatment for an eating disorder reached 11,174 in 2024/25.
Amy Dingle, Bramacare’s first patient and the platform’s namesake, said: “For anyone going through what I went through, it’s incredibly important that the people caring for you have the right information at the right time and are fully coordinated in their approach.
“AMY will give clinical teams the tools and insight they need to deliver the highest standard of care, providing patients with what I was fortunate to receive – a real chance at recovery.”
Additional services can also be accessed through the platform, including dedicated modules for dietetic planning, medication management, psychological intervention, occupational therapy and individualised risk assessments.
Dr Ramoo, Clinical Lead and Co-Founder of Bramacare, said: “Specialist eating disorder care is one of the most clinically complex areas of medicine.
“AMY was developed to provide clinical teams with a more effective way to make faster, safer, and more consistent decisions, while reducing the admin burden they already carry.”
The platform is currently in structured clinical evaluation, with first pilots starting in 2026 with NHS trust partners.
Related Content
Roche adds 2,176 NVIDIA Blackwell GPUs to its hybrid-cloud AI factory
Roche has expanded its global AI infrastructure with a NVIDIA AI factory, adding 2,176 high-performance …
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
MultiOmic Health and BIO4 Campus sign collaborative Memorandum of Understanding
MultiOmic Health (MOH), an artificial intelligence (AI)-enabled precision medicine biotechnology company and BIO4 Campus (BIO4), …
